证券记录 · 已归档季度
WAT
Waters Corporation · Healthcare · Medical - Diagnostics & Research
13被追踪持有人
-2Δ持有人
2.92M持有股份
$1.05B报告持仓市值
+1新建仓位
−3清仓
动量输入（同类管理人）：
持有人广度 -13.3% ·
股份流向 -0.7% ·
净新建仓位 -15.4%
— 公式
广泛派发 — 持股数量下降且持有人减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 162 | +2 | 70.18M | $26.88B | +7 | −5 |
| Q1 2026 | 163 | +5 | 66.62M | $20.68B | +11 | −7 |
| Q4 2025 | 157 | -1 | 42.72M | $16.21B | +1 | −1 |
| Q3 2025 | 21 | +1 | 20.77M | $6.22B | +2 | −2 |
| Q2 2025 | 18 | +1 | 20.33M | $7.10B | +1 | — |
| Q1 2025 | 14 | -1 | 6.37M | $2.34B | — | −1 |
| Q4 2024 | 15 | +1 | 6.13M | $2.27B | +1 | — |
| Q3 2024 | 13 | -2 | 2.92M | $1.05B | +1 | −3 |
| Q2 2024 | 15 | — | 2.95M | $853.36M | — | — |
持有人 · Q3 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (被动) | 1.42M | +1.2% | $508.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (被动) | 1.42M | +1.2% | $508.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Norges Bank ✦ (被动) | 829.63K | +22.9% | $298.58M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 271.16K | -7.5% | $97.59M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 271.16K | -7.5% | $97.59M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | PRIMECAP Management ✦ | 98.46K | -0.4% | $35.43M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 83.22K | +1.7% | $29.95M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 83.22K | +1.7% | $29.95M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 82.16K | -37.9% | $29.57M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 10 | Marshall Wace ✦ | 56.34K | +75.8% | $20.28M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Marshall Wace ✦ | 56.34K | +75.8% | $20.28M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Gotham Asset Management ✦ | 49.34K | -2.0% | $17.76M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 17.59K | +192.6% | $6.26M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 17.59K | +192.6% | $6.26M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 9.57K | 新增 | $3.44M | 0.0% | New | 1 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 4.90K | -8.2% | $1.76M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 4.90K | -8.2% | $1.76M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | Millennium Management ✦ | 4.02K | -87.4% | $1.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 978 | -98.8% | $351,972 | 0.0% | ▼ Trim | 2 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Arrowstreet Capital | $3.44M | 0.0% |
已清仓
| Baillie Gifford | $14.00M | 曾为 0.0% |
| Adage Capital Partners | $1.99M | 曾为 0.0% |
| Bridgewater Associates | $593,005 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 1,162 持有人, 92.59M 股份, $26.09B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2024 ·
方法论 ·
通过API获取此数据